Stockholm, May 12, 2016 — Nasdaq (Nasdaq: NDAQ) announced that Wilson Therapeutics AB (short name: WTX), a mid cap company within the health care sector, has started trading of its shares on the main market of Nasdaq Stockholm. Wilson Therapeutics is the 26th company to list at Nasdaq’s Nordic markets* in 2016.
Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, focused on developing novel therapies addressing unmet, medical needs in rare diseases. The company is committed to the development of its lead product, Decuprate, which is initially developed as a new treatment for Wilson Disease. Wilson Disease is a rare, genetic disease that causes serious copper poisoning, affecting approximately one in every 30 000 people worldwide. For more information, please visit www.wilsontherapeutics.com
“The listing on the Stockholm Stock Exchange is a significant milestone in the Company’s development history,” said Jonas Hansson, CEO of Wilson Therapeutics. “We are very pleased that we have secured the financing to continue to develop Decuprate all the way to the market with the goal of offering patients with Wilson Disease a novel therapy that addresses the large medical need that exists.”
“We are excited to welcome Wilson Therapeutics to the Nasdaq Stockholm main market,” said Adam Kostyál, senior vice president and head of European listings at Nasdaq. “Wilson Therapeutics joins our strong and growing health care sector, and we look forward to supporting them on their journey as a publicly traded company.”
*Main markets and Nasdaq First North at Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland and Nasdaq Stockholm.
Nasdaq (Nasdaq: NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,700 listed companies with a market value of over $9.3 trillion and nearly 17,000 corporate clients. To learn more, visit nasdaq.com/ambition or business.nasdaq.com.
Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland, Nasdaq Riga, Nasdaq Stockholm, Nasdaq Tallinn, Nasdaq Vilnius, Nasdaq Clearing and Nasdaq Broker Services are respectively brand names for the regulated markets of Nasdaq Copenhagen A/S, Nasdaq Helsinki Ltd., Nasdaq Iceland hf., Nasdaq Riga, AS, Nasdaq Stockholm AB, Nasdaq Tallinn AS, AB Nasdaq Vilnius, Nasdaq Clearing AB and Nasdaq Broker Services AB. Nasdaq Nordic represents the common offering by Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland and Nasdaq Stockholm. Nasdaq Baltic represents the common offering by Nasdaq Tallinn, Nasdaq Riga and Nasdaq Vilnius.
Cautionary Note Regarding Forward-Looking Statements
The matters described herein contain forward-looking statements that are made under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about Nasdaq and its products and offerings. We caution that these statements are not guarantees of future performance. Actual results may differ materially from those expressed or implied in the forward-looking statements. Forward-looking statements involve a number of risks, uncertainties or other factors beyond Nasdaq's control. These factors include, but are not limited to factors detailed in Nasdaq's annual report on Form 10-K, and periodic reports filed with the U.S. Securities and Exchange Commission. We undertake no obligation to release any revisions to any forward-looking statements.
|Media Relations Contact|
|+46 73 449 78 07|